Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05854303 · ClinicalTrials.gov registry record
Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction
A clinical trial of Opioid-Induced Esophageal Dysfunction, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 26
- Enrollment target
- 1
- Study location
NCT05854303: Recruiting study of Opioid-Induced Esophageal Dysfunction, sponsored by Mayo Clinic.
NCT05854303 is a study of Opioid-Induced Esophageal Dysfunction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05854303, a study of Opioid-Induced Esophageal Dysfunction, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).
Primary Outcome
Number of subjects to have resolution of opioid-induced esophageal dysfunction
Conditions Studied
Interventions
- BEHAVIORAL Opioid cessation
- OTHER No opioid cessation
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2026-11 |
What NCT05854303 shows while recruiting
NCT05854303 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 1 condition, with Opioid-Induced Esophageal Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Opioid cessation is the first listed.
NCT05854303 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05854303 about?
NCT05854303 is a clinical study titled "Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction". The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).
What is the current status of trial NCT05854303?
This trial is currently recruiting. The enrollment target is 26 participants. The study started on 2023-09-18. Estimated completion is 2026-11.
What conditions does trial NCT05854303 study?
This clinical trial studies the following conditions: Opioid-Induced Esophageal Dysfunction.
What interventions are being tested in trial NCT05854303?
The interventions under investigation include: Opioid cessation (BEHAVIORAL), No opioid cessation (OTHER).
Who is sponsoring clinical trial NCT05854303?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05854303 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI